Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-01-17 | Complegen (USA) Boehringer Ingelheim (Germany) | XenoGene™ Technology | licensing |
Licensing agreement | ||
2012-01-17 | JPT Peptide Technologies GmbH (Germany) IUCT (Spain) LEITAT Technological Center (Spain) | anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics | cancer | R&D |
Cancer - Oncology | R&D agreement |
2012-01-17 | AC Immune (Switzerland) University of Basel (Switzerland) | drugs for memory impairment | memory impairment | collaboration |
Neurodegenerative diseases - CNS diseases | R&D agreement |
2012-01-17 | Scil Proteins (Germany) Actavis (Switzerland) | Reteplase (Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin® for thrombolytic treatment of myocardial infarction) | myocardial infarction | supply |
Cardiovascular diseases | Production agreement |
2012-01-17 | Redbiotec (Switzerland) DKFZ - German Cancer Research Center (Germany) | chimeric VLPs (virus-like particles), containing proteins of different serotypes on one VLP. | HPV (human papillomavirus) infections | R&D |
Infectious diseases | R&D agreement |
2012-01-17 | Almac (UK) MGB Biopharma (UK) | MGB-BP3 | production |
Infectious diseases | Production agreement | |
2012-01-13 | Swedish Orphan Biovitrum SOBI (Sweden), Only for Children Pharmaceuticals (O4CP) (France) | bumetanide | diuresis and seizures in neonates | licensing |
CNS diseases | Licensing agreement |
2012-01-12 | Novalix (France) Teijin Pharma (Japan) | novel drug candidates against multiple targets across different therapeutic areas | undisclosed | R&D |
undisclosed | R&D agreement |
2012-01-12 | Covance USA) Inserm Transfert (France) Inserm Transfert Initiative (France) | discovery and early development studies | collaboration |
Collaboration agreement | ||
2012-01-11 | Octoplus (the Netherlands) undisclosed US-based pharmaceutical company (USA) | controlled release formulation of the client's therapeutic compound for local delivery into joints | R |
Collaboration agreement | ||
2012-01-10 | Qiagen (The Netherlands) Insight Genetics (USA) | ALK (anaplastic lymphoma kinase) biomarker | lung cancer | co-development |
Cancer - Oncology | Licensing agreement |
2012-01-10 | Qiagen (The Netherlands) Ipsogen (France) Personal Genome Diagnostics (USA) | IDH1/IDH2 biomarker | brain cancers, acute myelogenous leukemia (AML) and certain other malignancies | Cancer Oncology | Licensing agreement | |
2012-01-10 | Dako (Denmark) Amgen (USA) | diagnostic test for an Amgen cancer drug candidate targeted for a rare and deadly cancer | undisclosed cancer | development |
Cancer - Oncology | Development agreement |
2012-01-10 | Ventana Medical Systems (USA - a member of Roche Group - Switzerland) Pfizer (USA - NY) Cell Signaling Technology (USA) | immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements | non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer\'s XALKORI ® (crizotinib) | collaboration |
Diagnostic - Cancer - Oncology | Licensing agreement |
2012-01-10 | Sanofi (France) University of California, San Francisco (UCSF - USA) | drug targets that could lead to new therapies for both type 1 and type 2 diabetes | type 1 and type 2 diabetes | R&D |
Metabolic diseases | R&D agreement |
2012-01-10 | Sanofi (France) Foundation Medicine (USA) | genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates | cancer | R&D |
Cancer Oncology | Collaboration agreement |
2012-01-09 | Qiagen (The Netherlands) Max Planck Institute for Infection Biology (Germany) | molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime | tuberculosis | Infectious diseases | Development agreement | |
2012-01-09 | NiKem Research (Italy) Dualsystems Biotech (Switzerland) | drug/target profiling and drug discovery services | collaboration |
Collaboration agreement | ||
2012-01-09 | KalVista Pharmaceuticals (UK) JDRF (USA) | plasma kallikrein inhibitor | diabetic macular edema | R&D | Metabolic diseases - Ophtalmological diseases | |
2012-01-09 | Gentium (Italy) Swedish Orphan Biovitrum (Sweden) | defibrotide | prevention and treatment of hepatic veno-occlusive disease (VOD) | distribution | Digestive diseases |